There is a flurry of reactions to a draft recommendation from the U.S. Preventive Services Task Force. Although not formally released, the USPSTF is now recommending against PSA tests for prostate cancer. The American Urological Association, on the other hand, continues to assert that the PSA test is appropriate preventive care. (Ann McDonald of Harvard Medical School’s publishing arm has a nice summary of the reaction to the news.) The USPSTF previously sparked controversy in 2009, when it bumped up the recommended age for mammography from 40 to 50 years of age.
What type of health system would best respond to constantly evolving information like this?
Read the entire column at John Goodman's Health Policy Blog.